Skip to main content

Table 2 Key performance indices for detection of alterations in classic oncogenic drivers in NSCLC

From: Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer

Patient group Genomic alterations Sensitivity (%) PPV (%) Specificity (%)
SPU PLA SPU PLA SPU PLA
Entire cohort
(n = 71)
Drivers 50.0 63.5 96.3 97.1 99.8 99.8
EGFR 25.0 70.8 100 100 100 100
KRAS 83.3 75.0 100 100 100 100
ALK 75.0 37.5 85.7 100 98.5 100
ROS1 66.7 66.7 100 100.0 100 100
BRAF 100.0 100.0 100 50.0 100 99.0
MET 0.0 0.0 na na 100 100
RET 100 100 100 100 100 100
Centrally located lung tumors
(n = 39)
Drivers 63.0 59.3 94.4 100 99.5 100
EGFR 25.0 75.0 100 100 100 100
KRAS 85.7 57.1 100 100 100 100
ALK 71.4 28.6 83.3 100 97.1 100
ROS1 66.7 66.7 100 100 100 100
BRAF 100 100 100 100 100 100
MET nd nd nd nd nd nd
RET 100 100 100 100 100 100
Smokers
(n = 33)
Drivers 68.8 68.8 100 100 100 100
EGFR 33.3 66.7 100 100 100 100
KRAS 75.0 75.0 100 100 100 100
ALK 100 0.0 100 na 100 100
ROS1 100 100 100 100 100 100
BRAF 100 100 100 100 100 100
MET 0.0 0.0 na na 100 100
RET nd nd nd nd nd nd
LUSC
(n = 15)
Drivers 100 100 100 100 100 100
EGFR 100 100 100 100 100 100
KRAS nd nd nd nd nd nd
ALK 100 100 100 100 100 100
ROS1 nd nd nd nd nd nd
BRAF nd nd nd nd nd nd
MET nd nd nd nd nd nd
RET nd nd nd nd nd nd
  1. PLA plasma, PPV positive predictive value, SPU sputum supernatant. All sensitivity, PPV, and specificity values are expressed in percent. na, not applicable. nd, no alteration in indicated gene detected in reference (i.e. tumor biopsy) samples